Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M609509200 on October 19, 2006

J. Biol. Chem., Vol. 281, Issue 50, 38276-38284, December 15, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/50/38276    most recent
M609509200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Semenov, M. V.
Right arrow Articles by He, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Semenov, M. V.
Right arrow Articles by He, X.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

LRP5 Mutations Linked to High Bone Mass Diseases Cause Reduced LRP5 Binding and Inhibition by SOST*

Mikhail V. Semenov1 and Xi He2

From the Neurobiology Program, Children's Hospital Boston and Department of Neurology, Harvard Medical School, Boston, Massachusetts 02115

The low density lipoprotein (LDL) receptor-related protein 5 (LRP5) is a co-receptor for Wnt proteins and a major regulator in bone homeostasis. Human genetic studies have shown that recessive loss-of-function mutations in LRP5 are linked to osteoporosis, while on the contrary, dominant missense LRP5 mutations are associated with high bone mass (HBM) diseases. All LRP5 HBM mutations are clustered in a single region in the LRP5 extracellular domain and presumably result in elevated Wnt signaling in bone forming cells. Here we show that LRP5 HBM mutant proteins exhibit reduced binding to a secreted bone-specific LRP5 antagonist, SOST, and consequently are more refractory to inhibition by SOST. As loss-of-function mutations in the SOST gene are associated with Sclerosteosis, another disorder of excessive bone growth, our study suggests that the SOST-LRP5 antagonistic interaction plays a central role in bone mass regulation and may represent a nodal point for therapeutic intervention for osteoporosis and other bone diseases.


Received for publication, May 1, 2006 , and in revised form, October 10, 2006.

* This work was supported in part by Grant RO1GM57603 from the National Institutes of Health (to X. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence may be addressed: Division of Neuroscience, Enders 470, Children's Hospital, 61 Binney St., Boston, MA 02115. Tel.: 617-919-2260 (2257); Fax: 617-730-1953; E-mail: mikhail.semenov{at}childrens.harvard.edu. 2 W. M. Keck Foundation Distinguished Young Scholar and a Leukemia and Lymphoma Society Scholar. To whom correspondence may be addressed: Division of Neuroscience, Children's Hospital, 61 Binney St., Boston, MA 02115. Tel.: 617-919-2260 (2257); Fax: 617-730-1953; E-mail: xi.he{at}childrens.harvard.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
JDRHome page
R.L. van Bezooijen, A.L. Bronckers, R.A. Gortzak, P.C.W. Hogendoorn, L. van der Wee-Pals, W. Balemans, H.J. Oostenbroek, W. Van Hul, H. Hamersma, F.G. Dikkers, et al.
Sclerostin in Mineralized Matrices and van Buchem Disease
Journal of Dental Research, June 1, 2009; 88(6): 569 - 574.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Veverka, A. J. Henry, P. M. Slocombe, A. Ventom, B. Mulloy, F. W. Muskett, M. Muzylak, K. Greenslade, A. Moore, L. Zhang, et al.
Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION
J. Biol. Chem., April 17, 2009; 284(16): 10890 - 10900.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
R. Baron
Wnt Signaling, LRP5 and Gut Serotonin: Have We Been Targeting the Right Pathway for the Wrong Reasons?
IBMS BoneKEy, February 1, 2009; 6(2): 86 - 93.
[Full Text] [PDF]


Home page
BloodHome page
J. J. Pinzone, B. M. Hall, N. K. Thudi, M. Vonau, Y.-W. Qiang, T. J. Rosol, and J. D. Shaughnessy Jr
The role of Dickkopf-1 in bone development, homeostasis, and disease
Blood, January 15, 2009; 113(3): 517 - 525.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J.-M. Kaufman, A. Ostertag, A. Saint-Pierre, M. Cohen-Solal, A. Boland, I. Van Pottelbergh, K. Toye, M.-C. de Vernejoul, and M. Martinez
Genome-Wide Linkage Screen of Bone Mineral Density (BMD) in European Pedigrees Ascertained through a Male Relative with Low BMD Values: Evidence for Quantitative Trait Loci on 17q21-23, 11q12-13, 13q12-14, and 22q11
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3755 - 3762.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. V. Semenov, X. Zhang, and X. He
DKK1 Antagonizes Wnt Signaling without Promotion of LRP6 Internalization and Degradation
J. Biol. Chem., August 1, 2008; 283(31): 21427 - 21432.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
H K Datta, W F Ng, J A Walker, S P Tuck, and S S Varanasi
The cell biology of bone metabolism
J. Clin. Pathol., May 1, 2008; 61(5): 577 - 587.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. G. Robling, P. J. Niziolek, L. A. Baldridge, K. W. Condon, M. R. Allen, I. Alam, S. M. Mantila, J. Gluhak-Heinrich, T. M. Bellido, S. E. Harris, et al.
Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin
J. Biol. Chem., February 29, 2008; 283(9): 5866 - 5875.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
P. Leucht, J.-B. Kim, and J. A. Helms
Beta-Catenin-Dependent Wnt Signaling in Mandibular Bone Regeneration
J. Bone Joint Surg. Am., February 1, 2008; 90(Supplement_1): 3 - 8.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
P. t. Dijke, C. Krause, D. J. J. de Gorter, C. W.G.M. Lowik, and R. L. van Bezooijen
Osteocyte-Derived Sclerostin Inhibits Bone Formation: Its Role in Bone Morphogenetic Protein and Wnt Signaling
J. Bone Joint Surg. Am., February 1, 2008; 90(Supplement_1): 31 - 35.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
S. L. Dallas and L. F. Bonewald
Osteocytes Emerging From Obscurity. Meeting Report from the 29th Annual Meeting of the American Society for Bone and Mineral Research: September 16-19, 2007 in Honolulu, Hawaii, USA
IBMS BoneKEy, December 1, 2007; 4(12): 337 - 341.
[Full Text] [PDF]


Home page
EndocrinologyHome page
R. Baron and G. Rawadi
Targeting the Wnt/{beta}-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Endocrinology, June 1, 2007; 148(6): 2635 - 2643.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
P. V. Bodine
Wnt Signaling in Bone
IBMS BoneKEy, March 1, 2007; 4(3): 108 - 123.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
S. Ferrari
Single Gene Mutations and Variations Affecting Bone Turnover and Strength: a Selective 2006 Update
IBMS BoneKEy, December 1, 2006; 3(12): 11 - 29.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement